Clinical trialPhase 1Recruiting
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Phase 1 Dose Escalation Trial of ZM008, an Anti-LLT1 Antibody, as Single Agent Followed by Combination With Toripalimab in Patients With Advanced Solid Tumors
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Recruiting
- Study type
- Interventional
- Start
- 22 May 2024
- Expected end
- April 2027
- Enrollment
- 100 participants
- Sites
- 3
- Primary outcomes
- Nature and frequency of dose limiting toxicities per Common Toxicity Criteria for Adverse Events version 5; Change in systolic and diastolic BP,; Change in Heart Rate; Changes in Temperature measurements.; Change in pulse ox measurements on room air
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 2 April 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.